247 related articles for article (PubMed ID: 33822317)
1. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait.
Sanai FM; Al Khathlan A; Al Fadhli A; Jazzar AS; Hashim AM; Mansour E; Abaalkhail F; Hasan F; Al Mudaiheem H; Al Quraishi H; Bottomley J; Alswat KA; Al Ghamdi M; Farghaly M; Fathy M; Awad N; Mohamed O; Kozma S; Al-Hamoudi W; Al-Jedai A
Hepatol Int; 2021 Aug; 15(4):912-921. PubMed ID: 33822317
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
3. Management of nonalcoholic fatty liver disease in the Middle East.
Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
[TBL] [Abstract][Full Text] [Related]
4. The clinical & economic burden of treatment-resistant depression in the Gulf-Cooperation Council: The Kingdom of Saudi Arabia, Kuwait and the United Arab Emirates.
Akram A; Al-Sabahy M; Al-Jedai A; Almudaiheem H; Farghally M; Fallata E; Alibrahim O; Shoukry T; Basu S; Chalouhi D; Elsharkawy A; Mohamed O
Int J Methods Psychiatr Res; 2023 Sep; 32(3):e1952. PubMed ID: 36434774
[TBL] [Abstract][Full Text] [Related]
5. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
7. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
8. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
[TBL] [Abstract][Full Text] [Related]
9. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
[TBL] [Abstract][Full Text] [Related]
10. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.
Swain MG; Ramji A; Patel K; Sebastiani G; Shaheen AA; Tam E; Marotta P; Elkhashab M; Bajaj HS; Estes C; Razavi H
CMAJ Open; 2020; 8(2):E429-E436. PubMed ID: 32518095
[TBL] [Abstract][Full Text] [Related]
11. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
[TBL] [Abstract][Full Text] [Related]
12. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
[TBL] [Abstract][Full Text] [Related]
13. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
15. The humanistic and economic burden of atopic dermatitis among adults and adolescents in Saudi Arabia.
Elezbawy B; Fasseeh AN; Fouly E; Esba LCA; Al Abdulkarim H; Al-Haddab M; Al-Sheikh A; Altawil E; Al Turaiki A; Eshmawi M; Hamadah I; Tannira M; Dalle H; Aderian S; Roshdy A; Jaheen A; Hamad T; Abaza S; Kaló Z
J Med Econ; 2022; 25(1):1231-1239. PubMed ID: 36426726
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand.
Phisalprapa P; Prasitwarachot R; Kositamongkol C; Hengswat P; Srivanichakorn W; Washirasaksiri C; Treeprasertsuk S; Charatcharoenwitthaya P; Chaiyakunapruk N
BMC Gastroenterol; 2021 Mar; 21(1):135. PubMed ID: 33765931
[TBL] [Abstract][Full Text] [Related]
17. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
Adams LA; Roberts SK; Strasser SI; Mahady SE; Powell E; Estes C; Razavi H; George J
J Gastroenterol Hepatol; 2020 Sep; 35(9):1628-1635. PubMed ID: 32048317
[TBL] [Abstract][Full Text] [Related]
20. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
